Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

GtoImmuPdb_2017

86 views

Published on

IUPHAR Guide to IMMUNOPHARMACOLOGY poster. Presented at the BSI Congress 2017, Brighton, UK (6th December 2017) and at Pharmacology 2017, London, UK (13th December 2017.

Published in: Science
  • Be the first to comment

  • Be the first to like this

GtoImmuPdb_2017

  1. 1. Thank you to the BSI for supporting this poster: GtoImmuPdb Portal Aims ● A unique access-point to immunological data in GtoPdb ● An expert-curated database containing immunological information ● Develop new pages and extend search mechanism for immunological data ● Assist in the identification of novel therapeutic targets ● Assist in identifying small-molecules for experimental investigation S. D. Harding1 , E. Faccenda1 , S. Ireland1 , A. J. Pawson1 , J. L. Sharman1 , C. Southan1 , S. P. Alexander2 , S. Anderton3 , C. Bryant4 , A. P. Davenport5 , C. Doerig6 , D. Fabbro7 , F. Levi-Schaffer8 , M. Spedding9 , J. A. Davies1 1Centre for Integrative Physiology, School of Biomedical Sciences, University of Edinburgh, Edinburgh, UNITED KINGDOM, 2Life Sciences, University of Nottingham, Nottingham, UNITED KINGDOM,3MRC Centre for Inflammation Research, QMRI, University of Edinburgh, Edinburgh, UNITED KINGDOM, 4 Veterinary Medicine, University of Cambridge, Cambridge, UNITED KINGDOM,5 Clinical Pharmacology Unit, University of Cambridge, Cambridge, UNITED KINGDOM, 6 Department of Microbiology, Monash University, Clayton, AUSTRALIA, 7PIQUR Therapeutics AG, Basel, SWITZERLAND, 8School of Pharmacy, Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, ISRAEL, 9Spedding Research Solutions SARL, Le Vesinet, FRANCE. Introduction Background Immune/inflammatory/infection responses and disorders are a major focus of pharmacological R&D. Chronic diseases, aspects of ageing and progress of infection all have, or depend strongly on, an immune, or inflammatory, component. Being able to modulate these more effectively with better drugs would be immensely valuable. Development of these drugs will benefit from improved data exchange between the immunology expert and pharmacology expert communities. What is the Guide to IMMUNOPHARMACOLOGY Our Wellcome Trust-funded project to produce the IUPHAR Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb) addresses this need by providing a new portal to the existing IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb), that is both 'immunologist-friendly' for pharmacological information and 'pharmacologist-friendly' for accessing immunological agents and targets. GtoImmuPdb will be a freely-available, regularly updated and richly annotated resource. Curated by expert NC-IUPHAR* sub-committees, including additional contributors with expertise in immunity, inflammation and kinase biology. GtoImmuPdb Data The GtoP database has been enriched by tagging targets & ligands of immunological relevance and by linking these to immunological processes, cell types and relevant diseases. Beta-version v2.0 available at: www.guidetoimmunopharmacology.org The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) is an open access resource providing overviews of key properties, background reading and selective ligands of a wide range of biological targets. The searchable database provides quantitative information on drug targets and the prescription medicines and experimental drugs that act on them. For ligands, data on approved status, clinical use and mechanism of action are included. References * International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification 1. Harding SD, et al. (2018) The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new Guide to IMMUNOPHARMACOLOGY. Nucl. Acids Res. PMID: 29149325 2. Cell Ontology, http://obofoundry.org/ontology/cl.html ontology.org 3. Gene Ontology Consortium, http://geneontology.org Human targets in GtoPdb, 2017.5 release Ligand classes in GtoPdb, 2017.5 release The 2017.5 release (August 2017) of the database contains over 15,200 curated interactions across 1,684 human targets and 8,978 ligands. More specifically, the database contains 1,431 human targets that have quantitative interactions to a ligand. Immuno Process and Cell Type Data GtoImmuPdb presents a set of top-level immunological process and cell type categories against which targets in the database can be annotated and which form the basis of organising, navigating and searching for immunological process and cell type associations. Subsets of these ontologies are mapped to each top-level category. This then forms the basis of searches which will detect any cell type or process associations annotated with those terms (or their children). Target detailed view pages display process and cell type associations Including detailed curator comments and links to external references As of 9 Oct 2017 the development GtoImmuPdb held 455 protein targets and 816 ligands tagged as being of immunological relevance. GtoImmuPdb uses both Cell Ontology1 and Gene Ontology2 terms as controlled vocabularies against which to annotate. Displaying GtoImmuPdb data in detailed view of BTK Immuno Cell Types B cells Dendritic cells Granulocytes Innate lymphoid cells Macrophages & monocytes Mast cells Natural killer cells Other T cells T cells Stromal cells Immuno Processes Antigen presentation Barrier integrity B cell (activation) Cellular signalling Chemotaxis & migration Cytokine production & signalling Immune regulation Immune system development Inflammation T cell (activation) Tissue repair Targets Ligands Cell types Processes Disease Target family pages use a toggle to switch between GtoPdb & GtoImmuPdb views Ligand lists highlight immuno relevant ligands with new icons. Here showing inhibitors of BTK IUPHAR Guide to IMMUNOPHARMACOLOGY

×